Anthony has strategic oversight of the science and technology supported through NC3Rs; ensuring that the NC3Rs has a long-term and sustainable strategy for supporting the best science and technology and its use in practice to achieve 3Rs and wider scientific and economic benefits. He leads the CRACK IT open innovation programme.
View Anthony's Office-led projects
PA: Kayleigh Purdon
External roles
- Member of the British Standards Institute Biotechnologies Committee
- Member of the BioIndustry Association’s Science and Innovation Community (BIA SIComm)
- Member of the iGEM Foundation Safety Committee
- External Advisory Board member, CDT in Next Generation Organ-on-a-Chip Technology (COaCT), Queen Mary University of London
- Health and Environmental Sciences Institute (HESI), USA – Member of the Board of Trustees; June 2016 – June 2025. Board President June 2021 – June 2023
NC3Rs publications
Silito R, Sutherland J, Milne A, Giuliano C, Sigfridsson C, Rolf M, Cherian A, McClafferty M, Rossman E, Teuns G, Armstrong D, Holmes A (2025) Rodent home cage monitoring for preclinical safety pharmacology assessment: results of a multi-company validation evaluating nonclinical and clinical data from three compounds Frontiers in Toxicology doi: 10.3389/ftox.2025.1655330
Lilley E, Isbrucker R, Holmes A (2025) Integrating 3Rs approaches in WHO guidelines for the batch release testing of biologicals: Summary of NC3Rs final report to WHO Expert Committee for Biological Standardisation Biologicals doi: 10.1016/j.biologicals.2024.101778
Lilley E, Isbrucker R, Holmes A (2025) Integrating 3Rs approaches in WHO guidelines for the batch release testing of biologicals: Reports from a series of NC3Rs stakeholder workshops Biologicals doi: 10.1016/j.biologicals.2024.101777
Lilley E, Bruysters M, Das P, Gill S, Isbrucker R, Jones D, Holmes A (2023) Integrating 3Rs approaches in WHO guidelines for the batch release testing of biologicals: Responses from a survey of National Control Laboratories and National Regulatory Authorities Biologicals doi: 10.1016/j.biologicals.2023.101721
Lilley E, Coppens E, Das P, Galaway F, Isbrucker R, Sheridan S, Stickings P, Holmes A (2022) Integrating 3Rs approaches in WHO guidelines for the batch release testing of biologicals: Responses from a survey of vaccines and biological therapeutics manufacturers Biologicals doi: 10.1016/j.biologicals.2022.11.002
Lilley E, Isbrucker R, Ragan I, Holmes A (2021) Integrating 3Rs approaches in WHO guidelines for the batch release testing of biologicals Biologicals doi: 10.1016/j.biologicals.2021.10.002
Kleinstreuer N, Holmes A (2021) Harnessing the power of microphysiological systems for COVID-19 research Drug Discovery Today doi: 10.1016/j.drudis.2021.06.020
Jackson SJ, Prior H, Holmes A (2018) The Use of Human Tissue in Safety Assessment J Pharm Tox Meth doi: 10.1016/j.vascn.2018.05.003
Holmes A, Charlton A, Derby B, Ewart L, Scott A, Shu W (2017) Rising to the challenge: applying biofabrication approaches for better drug and chemical product development. Biofabrication doi: 10.1088/1758-5090/aa7bbd
Holmes A, Bonner, F, Jones D (2015) Assessing drug safety in human tissues - what are the barriers? Nature Reviews Drug Discovery doi: 10.1038/nrd4662
Abbott-Banner KH, Holmes A, Adcock I, Rao NL, Barrett E, Knowles R (2015) Meeting report: Models of respiratory disease symposium. Journal of Inflammation doi: 10.1186/1476-9255-10-s1-i1
Barnes P.J, Bonini S, Seeger W, Belvisi MG, Ward B, Holmes A. (2015) Barriers to new drug development in respiratory disease. Eur Respir J 45: 1197-207 doi: 10.1183/09031936.00007915
Edwards J, Belvisi M,Dahlen SE, Holgate S, Holmes A. (2015) Human tissue models for a human disease: what are the barriers? Thorax 70: 695-7 doi:10.1136/thoraxjnl-2014-206648
Percie du Sert N, Holmes A.M, Wallis M, Andrews PL. (2012) Predicting the emetic liability of novel chemical entities: a comparative study. British Journal of Pharmacology 165: 1848-1867 doi: 10.1111/j.1476-5381.2011.01669.x
Holmes A.M, Solari R, Holgate S.T, (2011) Animal models of asthma: value, limitations and opportunities for alternative approaches.Drug Discovery Today 16: 659-670 doi: 10.1016/j.drudis.2011.05.014
Holmes A.M, Creton S, Chapman K. (2010) Working in partnership to advance the 3Rs in toxicity testing Toxicology 12: 14-19 doi:10.1016/j.tox.2009.11.006
Westmoreland C, Holmes A.M, (2009) Assuring consumer safety without animals: Applications for tissue engineering Organogenesis 5: 67-72. doi: 10.4161/org.5.2.9128
Holmes A.M, Rudd JA, Tattersall FD, Q Aziz, Andrews PLR. (2009) Opportunities for the replacement of animals in the study of nausea and vomiting British Journal of Pharmacology 157: 865-80 doi: 10.1111/j.1476-5381.2009.00176.x
Holmes A, Brown R, Shakesheff K (2009) Engineering tissue alternatives to animals: applying tissue engineering to basic research and safety testing Regenerative Medicine 4: 579-592 doi: 10.2217/rme.09.26
For additional publications, see Ant's ResearchGate profile.
Qualifications
PhD, Biology
University of Cambridge, 2001 - 2004
The ins and outs of calcium signalling: regulation of calcium entry and release in electrically non-excitable cells.